Shots:

• The companies expand their existing collaboration to develop & commercialize RNAi therapies targeting SARS-CoV-2 utilizing Alnylam’s advances in lung delivery of novel conjugates of siRNA along with Vir’s infectious disease expertise
• Vir will be responsible for all development and commercialization of any selected DCs while Alnylam has an option to share equal profits & losses and may get development & commercialization milestones and royalties on sales of products resulting from the collaboration
• As per the expanded collaboration- companies can develop up to six novel siRNAs to treat infectious diseases. The partners are currently working on VIR-2218 (ALN-HBV02) for HBV- which is being evaluated in P-I/II study and is the first program to enter the clinic as a part of the infectious disease collaboration

Click here to­ read full press release/ article | Ref: Alnylam | Image: VIR